We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Celera and Abbott Collaborate To Identify Pharmacogenomic Markers

By LabMedica International staff writers
Posted on 19 Nov 2008
Celera Corp. More...
(Alameda, CA, USA) has entered into a collaborative research agreement with Abbott Labs (Abbott Park, IL, USA) to identify genetic markers for one of Abbot's investigational compounds. A major goal of this collaboration is to investigate if genetic variants Celera has identified can predict how patients may respond to treatment. The identification of treatment response markers may assist in further development of a drug.

Under the terms of this collaboration, Abbott will pay Celera an undisclosed fee to perform this study and any resulting companion diagnostic product could be developed by Celera and commercialized through its existing strategic alliance with Abbott.

"We're pleased to enter this collaboration with Abbott as it further reinforces Celera's commitment to personalized medicine,” said Thomas White, Ph.D., chief scientific officer at Celera. "The results of this study will provide new information on the correlation between genetic markers associated with disease and response to therapy. Routinely testing this general concept in early clinical trials may give us new and important insights to personalizing disease management.”

Celera is a healthcare business that provides personalized disease management through a combination of products and services incorporating proprietary discoveries. Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and improve patient management. Celera also commercializes a wide range of molecular diagnostic products through its strategic alliance with Abbott and the company has licensed other relevant diagnostic technologies developed to provide personalized disease management in cancer and liver diseases.

Abbott Labs is a diversified pharmaceuticals healthcare company that discovers, develops, manufactures, and sells pharmaceutical and nutritional products such as drug delivery systems, antibiotics, and prepared infant formulas.

Related Links:
Celera
Abbott Labs



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Platelet Function Analyzer
PL-12
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders

Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more

Microbiology

view channel
Image Credit: 123RF

FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample

Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.